STOCK TITAN

Enzo Biochem, Inc. - $ENZ STOCK NEWS

Welcome to our dedicated page for Enzo Biochem news (Ticker: $ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enzo Biochem's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enzo Biochem's position in the market.

Rhea-AI Summary
Enzo Biochem, Inc. (ENZ) reports a strong second quarter with revenue growth, improved gross margins, and increased net income. The Life Science division saw a 14% revenue increase, driven by a 25% growth in the United States. The company ended the quarter with $60.2 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary
Enzo Biochem, Inc. announced the voting results from its Annual Meeting, including the election of new Board of Directors members, the non-approval of executive officers' compensation, and the ratification of the appointment of an independent registered public accounting firm. Additionally, Kara Cannon and Patricia Eckert were appointed as permanent Chief Executive Officer and Chief Financial Officer, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Enzo Biochem, Inc. (NYSE: ENZ) announced a 10% year-over-year revenue improvement in its Life Sciences division for the first quarter ended October 31, 2023. The gross margin increased by approximately 900 basis points, and working capital improved to $59.2 million. However, the net loss was $6.6 million, and SG&A expenses increased by $1.4 million year-over-year. The company aims to drive future growth and increase shareholder value through new products and strengthened service offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Enzo Biochem, Inc. announced financial results for Q4 2023 and FY 2023. They closed the sale of assets for $113.3 million, divesting their clinical laboratory operations. Enzo Life Sciences' Q4 revenue increased by 20% sequentially and 13% YoY. Gross margin improved to 53.3% (excluding inventory provision). Cash and cash equivalents increased to $83.4 million. Full-year highlights include increased revenues in the US market and improved margin to 42.5%. Net income for FY23 was $20.3 million. Steven J. Pully was appointed Chairman of the Board, and Kara Cannon became Interim CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
Enzo Biochem, Inc. appoints Steven J. Pully as Chairperson of the Board and Chair of the Audit Committee. Pully brings legal, corporate governance, and financial skills to facilitate the company's growth strategy. He is a partner at Speyside Partners and serves on the boards of various companies. Pully's experience spans multiple industries and he will play a central role in Enzo's future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
management
-
Rhea-AI Summary
Enzo Biochem CEO resigns, COO becomes interim CEO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
Rhea-AI Summary
Enzo Biochem has completed the sale of certain assets of Enzo's Clinical laboratory division to Laboratory Corporation of America Holdings (Labcorp) for a purchase price of $113,250,000 in cash. Enzo Biochem will cease its clinical laboratory operations as a result of this transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
Enzo Biochem, Inc.

NYSE:ENZ

ENZ Rankings

ENZ Stock Data

53.27M
39.35M
24.19%
39.57%
1.41%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
FARMINGDALE

About ENZ

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.